Ertugliflozin and Sitagliptin

Hypoglycaemic excluding Insulin · Dipeptidyl peptidase-4 inhibitor/Sodium-glucose co-transporter 2 (SGLT2) inhibitors

Indications

Type 2 diabetes mellitus in patients when individual agent alone does not provide adequate response.

Dosage

Adults: 5/100 mg once daily, in the morning, with or without meals. Increase to 15/100 mg once daily if additional glycaemic control is required. Children: Not recommended.

Adverse Effects

Female genital mycotic infections. Upper respiratory tract infections, nasopharyngitis, headache. Hypoglycaemia.

Risk Factor (Pregnancy/Lactation)

Pregnancy: Contraindicated in pregnancy. Lactation: Contraindicated or not recommended. Contraindications: Severe renal impairment, end-stage renal disease, or dialysis. Pancreatitis. Ketoacidosis. Precautions: Renal impairment. Hypotension, urosepsis and pyelonephritis. Heart failure. Genital mycotic infections. Increased LDL-C. Severe arthralgia. Pemphigoid. History of prior amputation, peripheral vascular disease, neuropathy, diabetic foot ulcer. High cholesterol levels. Gallstones.

Interactions

Insulin, insulin secretagogues. Digoxin.

Advice to Patient

Take with or without meals, in the morning. Take missed dose as soon as you remember unless it is almost time for next dose. Inform prescriber if there is fever, stress, trauma, infection or requirement of surgery.

Pharmacokinetics

ERTUGLIFLOZIN: Metabolism: Hepatic. Half-life elimination: 16.6 hrs. Time to peak, plasma: 1 hr. Excretion: Urine (1.5%). Faeces (33.8%). SITAGLIPTIN: Absorption: Rapid. Metabolism: Hepatic (not extensively metabolized). Bioavailability: Approx. 87%. Half-life elimination: 12.4 hrs. Time to peak, plasma: 1-4 hrs. Excretion: Urine (87%). Faeces (13%).

Compiled by Healify Pharmacy from published drug references. How we compile it →

Always consult a pharmacist or doctor.